BAJEL:NSE:NSE-BAJEL PROJECTS LTD (INR)

COMMON STOCK | Utilities - Regulated Electric |

Last Closing

USD 320.95

Change

+20.70 (+6.89)%

Market Cap

N/A

Volume

3.25M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-07-05 )

Largest Industry Peers for Utilities - Regulated Electric

Symbol Name Price(Change) Market Cap
NTPC:NSE NTPC Limited

-4.90 (-1.13%)

USD 4,244.23B
POWERGRID:NSE Power Grid Corporation of Indi..

-5.30 (-1.54%)

USD 3,102.21B
NLCINDIA:NSE NLC India Limited

-6.60 (-2.33%)

USD 382.78B
CESC:NSE CESC Limited

+0.84 (+0.43%)

USD 257.81B
GIPCL:NSE Gujarat Industries Power Compa..

+1.19 (+0.51%)

USD 35.19B
DPSCLTD:NSE DPSC Limited

-0.39 (-2.02%)

USD 18.80B
ENERGYDEV:NSE Energy Development Company Lim..

+0.11 (+0.46%)

USD 1.20B

ETFs Containing BAJEL:NSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Utilities - Regulated Electric) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 143.51% 100% F 98% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 143.51% 100% F 98% N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike